Mitchel is a reporter for MDedge based in the Philadelphia area. He started with the company in 1992, when it was International Medical News Group (IMNG), and has since covered a range of medical specialties. Mitchel trained as a virologist at Roswell Park Memorial Institute in Buffalo, and then worked briefly as a researcher at Boston Children's Hospital before pivoting to journalism as a AAAS Mass Media Fellow in 1980. His first reporting job was with Science Digest magazine, and from the mid-1980s to early-1990s he was a reporter with Medical World News. @mitchelzoler
News
Experts tout immediate quadruple therapy for HFrEF patients
Recent evidence cemented four drug classes as foundational pillars of HFrEF treatment. The answer to how to start them: immediately and all at...
News
Entresto halves renal events in preserved EF heart failure patients
The PARAGON-HF trial of sacubitril/valsartan in patients with heart failure with preserved ejection fraction didn’t meet its primary outcome but...
News
T2D treatments create tension between glycemic and cardiovascular goals
Recent society guidelines clash on whether metformin or newer drug classes should start first when treating patients with type 2 diabetes.
News
Adrenal vein sampling looms as choke point for aldosteronism assessment of hypertensives
Imaging’s surprising unreliability for finding unilateral adrenal adenomas leaves pricey and hard-to-run adrenal vein sampling the only option.
News
Empagliflozin cut PA pressures in heart failure patients
The drops in pulmonary artery pressure were modest but large enough to be clinically meaningful, they appeared quickly, and increased over time....
News
Music’s charms may soothe heart failure’s effects
Evidence builds that music, either heard or sung, exerts measurable benefits for heart failure and other cardiovascular diseases.
News
Dapagliflozin’s CKD performance sends heart failure messages
The recently reported DAPA-CKD trial results focused on patients with renal disease, but the findings also resonate for heart failure clinicians...
News
Higher glycemic time in range may benefit T2D patients
A post hoc analysis linked greater blood-glucose time in range with fewer hypoglycemic, microvascular, and major adverse cardiac events in T2D...
News
DAPA-CKD resets eGFR floor for safe SGLT2 inhibitor use
Until now, SGLT2 inhibitors were for patients with an eGFR of at least 30 mL/min per m2. New evidence moves the threshold down to 25....
News
VERTIS CV: Ertugliflozin’s proven benefits fall short of other SGLT2 inhibitors
Added analyses from ertugliflozin’s cardiovascular outcome trial hint at SGLT2 inhibitor–consistent benefits, but proven benefits remain scant.
News
Survival after kidney transplantation lags in diabetes patients
Overall U.S. survival after kidney transplantation rose during 2000-2018, but less so in patients with type 1 or type 2 diabetes.
News
‘Dose response’ between exercise and improvement in diabetes
As adherence to a thrice-weekly, supervised exercise class rose, A1c levels fell. Aerobic exercise, or a combination of aerobic and resistance...
News
IMPACT-AFib: Single mailing fails to budge oral anticoagulant uptake for AFib
Researchers examined whether a minimal intervention – a single educational mailing – could boost oral anticoagulant use among AFib patients. It...